ArticleWorld journal of urology2025
UNIK (Urologic Non-Neoplastic Investigation of Kidneys): a machine learning approach to decode benign lesion.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [European journal of nuclear medicine and molecular imaging · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePredicting the likelihood of benign neoplasia in patients with suspected renal cell carcinoma (RCC) is a cornerstone of presurgical planning. We sought to create and validate U.N.I.K., a machine learning (ML) model capable of predicting benign lesions on final histological report.
methodsWe queried the INMARC database for patients with cT1ab-2ab renal neoplasms. The primary outcome was the development of an ML model to predict benign neoplasia. The secondary objective was to compare ML performance to that of a logistic regression (LR) model. The ML algorithms evaluated included random forest, extreme gradient boosting (XGBoost), and light gradient boosting machine (LightGBM). Model performance was assessed using receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC).
resultsA total of 3,093 patients were analyzed, with benign histology reported in 7.1% of cases. LR identified the following as significant predictors: female sex (OR 2.14, p < 0.001), diabetes (OR 5.95, p < 0.001), tumor size (OR 0.86, p < 0.001), preoperative CRP < 1 mg/L (OR 1.69, p < 0.001), serum calcium (OR 1.81, p < 0.001), Charlson Comorbidity Index (OR 0.52, p < 0.001), cystic lesion (OR 12.31, p < 0.001), De Ritis ratio ≥ 0.9 (OR 1.49, p = 0.03), preoperative proteinuria (OR 0.12, p < 0.001), and Karnofsky Performance Status (OR 0.90, p < 0.001), with an AUC of 0.89. XGBoost showed the best performance (AUC 0.94) and was used to develop the U.N.I.K. MODEL: Limitations include the retrospective design.
conclusionWe developed a point-of-care model capable of predicting benign tumors with high accuracy. U.N.I.K. may refine clinical decision-making and reduce the burden of surgical overtreatment.
Indexed as
Identifiers
40467874What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.